Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
Roche enters $2 billion cancer drug agreement with Nurix Therapeutics ZURICH, June 8 (Reuters) - Swiss pharmaceutical giant Roche ROPC.S has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics NRIX.O of up to $2.3 billion, the company said on Monday.
The deal focuses on blood cancer drug bexobrutideg, which degrades targeted proteins and is planned to enter a phase III clinical trial initiation for chronic lymphocytic leukaemia (CLL) in the summer
Nurix will receive $700 million upfront, with possible payouts for development, regulatory and sales milestones
"We believe bexobrutideg could represent a major leap forward in the fight against complex blood cancers and other diseases," Levi Garraway, Roche chief medical officer and head of global product development said
The deal is expected to close in the third quarter of 2026
Development costs for the drug will be covered 60% by Roche and 40% by Nurix
The companies will co-commercialise the drug in the United States, where they will split the profits and losses equally, while Roche will commercialise outside of the U.S., paying Nurix royalties
(Reporting by Marleen Kaesebier and Oliver Hirt, Editing by Friederike Heine)
((marleen.kaesebier@thomsonreuters.com))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis